PLRX — PLIANT THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1746473 ·
Last close
$0.66
Market Cap
$40.93M
52W High
$1.67
52W Low
$0.65
ADV30
412,869
Next earnings
2026-11-12
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -25,742,000 -24,377,000 169,877,000 26,568,000 43,245,000
Jun 2026 0 — -23,862,000 -22,371,000 189,881,000 24,883,000 42,955,000
Mar 2026 0 — -21,772,000 -20,040,000 202,596,000 22,190,000 37,430,000
Dec 2025 0 — -23,577,000 -23,577,000 225,228,000 45,445,000 44,023,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-70,895,000
Investing CF
$41,079,000
Financing CF
$-32,121,000
CapEx
$-374,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.49
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-901,807,000
Inventory
—
Receivables
$873,000
ST Investments
$133,218,000
EBIT TTM
$-91,338,000
Pretax Income TTM
$-92,289,000
Interest Exp TTM
$951,000
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -156,373,000 -149,344,000 225,228,000 44,023,000 181,205,000 -128,336,000
Dec 2024 0 -228,365,000 -210,304,000 396,949,000 92,868,000 304,081,000 -155,503,000
Dec 2023 1,580,000 -184,145,000 -161,336,000 512,154,000 38,578,000 473,576,000 -116,361,000
Dec 2022 9,685,000 -127,200,000 -123,321,000 350,613,000 37,271,000 313,342,000 -94,631,000

TTM Snapshot

Revenues TTM
$117,786,000
NetIncome TTM
$-92,289,000
OpCashFlow TTM
—
Assets (Latest)
$189,881,000
Forward EPS
$-1.29

Peers — same industry

TickerNameMarket CapLastDaily %
DWTX Dogwood Therapeutics, Inc. $41.29M $1.08 —
ELTX Elicio Therapeutics, Inc. $40.48M $1.43 —
TLPH TALPHERA, INC. $41.61M $0.80 —
ALDX Aldeyra Therapeutics, Inc. $41.88M $0.69 —
ATNM Actinium Pharmaceuticals, Inc. $42.45M $1.35 —

News headlines (Yahoo Finance, 1h cache)

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-12 21:05 · Yahoo
Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
2026-11-09 13:30 · Yahoo
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
2026-10-29 20:05 · Yahoo
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
2026-10-20 12:30 · Yahoo
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
2026-10-19 20:05 · Yahoo
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
2026-09-30 20:10 · Yahoo
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
2026-08-18 12:30 · Yahoo
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-11 20:05 · Yahoo
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
2026-07-13 12:30 · Yahoo
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
2026-05-06 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.